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i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 4 2 7e4 3 4432hypertension. Moreover, sympathetic overactivity is a key
component of the signaling pathways altered in
hypertension-related cardiac remodeling. However, in the
LIFE study and other related meta-analysis, antihypertensive
treatment with beta blocker-based therapy resulted in less
LVH regression than an ACEI or ARB-based strategy. The
diminished efficacy of beta-blockers on LVH reduction might
reside in their inability to decrease myocardial fibrosis. In
contrast, RD strategy has shown significant LVH regression
and improvement of diastolic function. It has also been noted
that RD-induced LVH regression was not exclusively associ-
ated with BP reduction.
However, the number of patients involved in this trial was
small and the follow up duration was only 6 months.
Furthermore, no comparator therapy was available for this
group of resistant hypertension patients. A role for the
sympathetic nervous system in long-term control of body
fluid volumes and arterial pressure is controversial for several
reasons, including the difficulty in assessing the functional
effects of the renal nerves under chronic conditions. A key
issue with this RF energy denervation approach is whether
anatomical and/or functional re-growth of renal sympathetic
nerves occur, abrogating the long term BP-lowering benefits.
Such re-growth has been observed in other conditions where
sympathetic nerves have been disrupted, such as in organ
transplantation. A large randomized controlled trial with
long-term follow up is required.
ALTITUDE halted: Adverse events when aliskiren added toACEI, ARB therapy.
ALTITUDE study
Background: Patientswith type 2 diabetes are at increased risk
of macro- and microvascular disease, and the presence of
albuminuria and/or reduced kidney function further
enhances macrovascular risk. ACEI reduce both macro- and
microvascular events, yet the residual renal and cardiovas-
cular risk still remains high. Aliskiren a novel oral direct renin
inhibitor that unlike ACEI and ARBs, lowers plasma renin
activity, angiotensin I and angiotensin II levels, may thereby
provide greater benefit compared to ACEI or ARB alone.
Methods: The primary objective of the ALTITUDE trial was
to determine whether aliskiren 300 mg once daily, reduces
cardiovascular and renal morbidity and mortality compared
with placebo when added to conventional treatment
(including ACEI or ARB). ALTITUDE was an international,
randomized, double-blind, placebo-controlled, parallel-group
study, which included three categories of high-risk patients
with type 2 diabetes (aged 35 years): those with either
urinary albumin/creatinine ratio (UACR) 200 mg/g; micro-
albuminuria (UACR)20<200mg/g and eGFR30<60mL/min/
1.73 m2; and thirdly, those with a history of cardiovascular
disease and eGFR 30<60 mL/min/1.73 m2 with or without
microalbuminuria. ALTITUDE was an event driven trial that
aimed to randomize 8600 patients with a planned follow-up
time of 48 months. The primary outcome measure was time
to first event for the composite endpoint of cardiovasculardeath, resuscitated death, myocardial infarction, stroke,
unplanned hospitalization for heart failure, onset of end-stage
renal disease or doubling of baseline serum creatinine
concentration. Secondary endpoints included a composite CV
endpoint and a composite renal endpoint.
Perspective
The trial was prematurely halted by data safety and moni-
toring board (DSMB) as there was an increase in adverse
events and no apparent benefits among patients randomized
to aliskiren.
In making its recommendation, the DSMB noted that
the active-treatment group experienced an increased
incidence of nonfatal stroke, renal complications, hyper-
kalemia, and hypotension over 18e24 months of follow-up.
The committee concluded that patients were unlikely to
benefit from aliskiren on top of standard antihypertensive
therapy.
Though earlier this year, ACCELERATE trial looking at
aliskiren in combination with a calcium-channel blocker
showed positive results and the FDA had approved both
a dual- and triple-combination drug including aliskiren, but
the recommended combination did not include an ACEI or
ARB.
ALTITUDE study tried to evaluate the effect of direct
renin inhibition in diabetic patients who are likely to
experience the compensatory rise in plasma renin and
other downstream RAAS components, including aldoste-
rone, induced by ACEI or ARBs. The damaging impact of
aldosterone escape is well established in CVD and renal
disease during ACEI or ARB treatment. Aliskiren was
expected to block the compensatory rise in RAAS activity,
and offer a novel approach to dual blockade of the RAAS.
Although recent results of both VALIANT and ONTARGET
showed no clinical benefits of the combination of effective
doses of an ACEI and ARB, it was presumed combining
either of them with aliskiren would offset potential dele-
terious effects of compensating rennin activation. However,
the results of ALTITUDE study showed the combination to
be detrimental.
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Objectives: Does coronary artery calcification (CAC) in
patients with cardiac symptoms correlate with severity of
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 4 2 7e4 3 4 433coronary artery disease (CAD) by coronary computed tomog-
raphy angiography (CCTA)?Editor’s perspective
This large multinational study shows that performing
a calcium scoring in a patient undergoing a CTA does not
provide additional information in terms of risk assessment.
Even a calcium score of 0 can have a significant event rate if
there is a noncalcified plaque of more than 50%. Hence
a contrast CTA is important to clearly delineate the presence
or absence of CAD.2. Harold I. Litt, Constantine Gatsonis, Brad Snyder, et al.,
CT angiography for safe discharge of patients with
possible acute coronary syndromes, N. Engl. J. Med. (2012
March 26).Objectives: Does a coronary CTA strategy in patients pre-
senting with chest pain in the ER lead to a safe early discharge
strategy with a low cardiac event rate on follow up?Editor’s perspective
This large multicentre nonindustry sponsored trial was con-
ducted at five centres in the US with a prime objective of
demonstrating the accuracy and safety of using a CTA based
strategy in patientswith intermediate probability of chest pain.
The rationale to conduct the study was the high rate of
noncardiac causes found among patients with possible acute
coronary syndromes.
Two groups were randomly assigned patients one to a CTA
strategy and the other to a traditional strategy .The primary
outcome was the absence of MI and cardiac death in the first
30 days after presentation.
1370 subjects were enrolled. Of the 640 patients with
a negative CTA exam none had a primary outcome. The
patients in the CTA group had a higher rate of discharge (49.6%
vs 22.7%), a shorter length of stay (18 h vs 24.8 h) and a higher
rate of CAD detection (9% vs 3.5%) with an adverse event in
both groups.
In a real world setting the CTA based strategy for low to
intermediate risk patients with possible acute coronary
syndrome appears to allow the safe discharge of patients from
the ER. This strategy can be replicated in our country as the
number of coronary enabled scanners are increasing and so is
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Introduction: Epidemiology of sudden cardiac death (SCD) in
India is understudied.
Methods: We assessed proportion of SCD among total
mortality in a population in Southern India using a staged,
questionnaire-based kindred-wide approach. Detailed ques-
tionnaires (DQs) were completed by medical trainees from 8
medical colleges. Preliminary questionnaires evaluated total
deaths in the kindred of a respondent. Deaths due to obvious
non-cardiac causes were excluded. DQs were completed for
the remaining deaths and categorized using a three-member
adjudication system.
Results: A total population of 22,724 was evaluated by 478
respondents (278 M and 200 F). Out of a total of 2185 deaths,
1691 (77.4%) were recallable. A total of 173 (10.3%; 128 M and
45 F; mean age e 60.8  14 years) deaths were adjudicated as
SCD. Of these, 82 (47.3%) were 60 years of age. Prior MI, LV
dysfunction and prior aborted SCDwere found in 33.5%, 22.5%
and 5.7% respectively. Coronary artery disease (CAD) was
observed in 66 (38%) and acute myocardial infarction docu-
mented in 30 (17%). At least 1 of 3 CAD risk factors e hyper-
tension, diabetes, or smoking was observed in 80.6%.
Proportion of subjects with at least one risk factor for CAD
were similar in the age groups above and below 50 years
(67.6% vs. 81.7%, p ¼ 0.065).
Conclusions: SCD contributed to 10.3% of overall mortality
in this population from Southern India. On an average, SCD
cases were 5e8 years younger compared to populations
reported in thewestern hemisphere, with a high prevalence of
major risk factors for CAD.Perspective
The epidemiology of sudden cardiac death (SCD) is impre-
cise even in developed countries with electronic records and
national indexing of deaths. Given the lack of medical
records, innovative methods have been used to classify the
cause of death like a ‘verbal autopsy’, i.e ‘a systematic
retrospective inquiry of family members about the symp-
toms and signs of illness prior to death’. In this article, Rao
et al. reported a large population-based study which
surveyed the incidence of SCD through the novel use of
staged detailed questionnaires in Southern India. Through
these questionnaires administered to family members of
medical students, a population of 22,724 was surveyed and
a sample of 2185 deaths was obtained. Deaths were cate-
gorized by a 3-member adjudication system. They found
that SCD contributed to 10.3% of total mortality. The mean
age of the SCD population was 60.8  14 years (35e85 years)
and 55.5% of them were in the age group 50e70 years.
Coronary artery disease (CAD) was found in 38% and 17%
had documented acute myocardial infarction but only about
10% of them underwent revascularization. In the SCD
cohort, 80.6% had at least one of the risk factors e diabetes,
hypertension or smoking and this proportion was similar in
subjects aged above and below 50 years. Amongst the SCD
